Treatment After Progression of Fulvestrant Among Metastatic Breast Cancer Patients

What Comes After Fulvestrant? A Real World Multicenter Retrospective Study-Treatment After Progression of Fulvestrant Among Metastatic Breast Cancer Patients in China

What Comes After Fulvestrant? A Real World Multicenter Retrospective Study-Treatment After Progression of Fulvestrant Among Metastatic Breast Cancer Patients in China.

There is no evidence of treatment after progression of Ful. We retrospectively evaluated HR+, HER2- MBC patients failed on Ful 500mg as first line or second line therapy from 2014 to 2017 in 6 institutions. Treatment pattern, PFS, OS and safety were analyzed to figure out the situation and efficacy of treatment after Fulvestrant.

Inclusion Criteria:

• Patients who were treated with Fulvestrant between June 2014 to June 2017 as first line or second line therapy
• Patients received subsequent treatment after progressing on Fulvestrant for at least one cycle (>1 month)
• Complete medical history was available

Exclusion Criteria:

• Subsequent treatment was not standard therapy (cannot be classified into endocrine therapy/ chemotherapy)
• Medical history was incomplete